You can’t argue against facts.
Highlighting facts and missteps is not disparaging, it’s the truth. Just one single example:
I wonder out loud if any people felt misled about the conjunctivitis dream.
2013 CEO via ASX release:“SPL7013 has the potential to be a first-in-class anti-viral agent for viral conjunctivitis (VC)” ~ a direct quote from CEO !!
”A global market of US$700m exists for effective VC treatments” ~ a direct quote from CEO !!!
”Based on feedback from potential partners and clinicians this opportunity is being advanced..” - a direct quote from CEO !!
2014:
2015:
2016:
2017:
2018:
2019:
2020:
2021:
At the 2021 Starpharma AGM during Q&A with the CEO, shareholders were made aware that SPL7013 and viral-conjunctivitis was now not a priority.
This is truly shameful. But this is quite typical of what Starpharma do, and continue to do. Hello … the Indian distribution deal which supposedly was well advanced in partnering discussions for Viraleze. Still waiting…
DYOR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $54.36M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $53.97K | 420.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70507 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 493895 | 3 |
View Market Depth
| Last trade - 15.14pm 19/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |